At the 17th International Symposium on Atherosclerosis, the latest data of clinical trials and drug development were presented in Clinical Breakthroughs Sessions.
The presenters briefly summarise their findings.
You can download the Clinical Breakthroughs abstracts.

 

 

3 minute education • 15-6-2015, ISA Amsterdam, Prof. Eli Roth

PCSK9-inhibitor less frequently administered may be effective treatment option

ISA2015 | Clinical Breakthroughs The ODYSSEY CHOICE I evaluated the efficacy of PCSK9-inhibitor alirocumab given once every four weeks instead of every two weeks. Prof. Eli Roth considers this dosing scheme a good option for patients who prefer monthly injections.

3 minute education • 16-6-2015, ISA2015, Amsterdam, Jennifer Robinson

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.

3 minute education • 16-6-2015, ISA2015, Amsterdam, Peter Toth

Ezetimibe does not disturb glycaemic control

ISA2015 | Clinical Breakthroughs Peter Toth presented data of a pooled analysis of clinical trials, in which no evidence was seen that ezetimibe increases fasting glucose, as opposed to statins.

3 minute education • 15-6-2015, ISA2015, Amsterdam, Prof. Frederick Raal

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.

3 minute education • 25-5-2015, ISA Amsterdam, May 25, 2015, Børge Nordestgaard

Lowering triglycerides while raising LDL-c: is this a problem?

ISA2015 | Clinical Breakthroughs Prof. Børge Nordestgaard (Copenhagen, Danmark) discusses results with a novel specific PPAR alpha-modulator that lowers triglycerides, remnant cholesterol and apoCIII, but raises LDL-c. A Danish registry suggests that this combination may actually be a beneficial lipid profile.

3 minute education • 25-5-2015, ISA Amsterdam, May 25, 2015, Allyson Morton

Increase in LDL may not always be associated with increase in CV risk

ISA 2015  Allyson Morton (Boston, USA) presented a follow-up study of the EVOLVE trial, that showed that omega-3 carboxylic acid treatment reduced apoCIII levels in whole plasma, and in HDL and LDL. The levels of LDL without apoCIII were reduced, which has a weak relation to CV risk.

3 minute education • 24-5-2015, ISA Amsterdam, May 24, 2015, Dr. Paul Barton Duell

Strong reduction CV events in FH patients with ApoB-inhibitor

ISA 2015  In a Clinical Breakthrough Session, dr. Paul Barton Duell (endocrinologist, Portland, USA) presented a striking reduction of MACE with treatment with the antisense oligonucleotide against apoB mRNA mipomersen in a very high risk population.

News • 25-5-2015

CETP-inhibitor reduces non-HDL-cholesterol via reducing PCSK9 and enhancing hepatic remnant clearance

ISA 2015 Using a humanised mouse model, investigators reveal mechanism via which CETP-inhibitor anacetrapib reduces non-HDL-c.

News • 25-5-2015

Omega-3 carboxylic acids significantly reduce plasma ApoCIII

ISA 2015 A new analysis of the EVOLVE trial demonstrates that 12 weeks of treatment with omega-3 carboxylic acids significantly reduce total plasma apoCIII and apoCIII-containing lipoproteins as compared to placebo, in addition to lowering serum triglycerides.

News • 25-5-2015

Promising triglyceride lowering with first-in-class structurally enhanced fatty acid

ISA2015 Primary endpoint met in first proof-of-principle study with the experimental agent icosabutate in patients with hypertriglyceridaemia, at a lower dose than conventional prescription omega-3 therapies.

News • 24-5-2015

Investigational drug has remodeling effect on HDL particles and induces cholesterol efflux

ISA 2015 Herman Kempen (Zurich, Switzerland) presented a new drug that may reduce the atherosclerotic plaque. MDCO-216, a complex of dimeric recombinant apolipoprotein A-1 Milano and a phospholipid (POPC), developed to mimic pre-beta HDL, induced ABCA1 mediated cholesterol efflux, and rapid HDL remodeling was seen. MDCO-216 was well tolerated.

News • 24-5-2015 • Presented by: dr. Anatol Kontush (Paris, France)

Novel approach bears potential to reduce inflammation in the arterial wall

ISA 2015 Dr. Anatol Kontush (Paris, France) presented a novel approach to reduce inflammation in the arterial wall. Phosphatidylserine-enriched artificial HDL particles lower inflammatory response in macrophages and in a mouse model of atherosclerosis.

News • 26-5-2015

Ezetimibe does not increase fasting glucose more than statins alone in non-diabetic, hypercholesterolemic patients

ISA 2015 A pooled analysis shows that addition of the cholesterol absorption inhibitor ezetimibe to statins does not increase fasting serum glucose, as compared to doubling the statin dose.

News • 25-5-2015

Gene therapy to stimulate tissue repair remodels hearts in severe ischaemic heart failure

Gene therapy with stromal cell-derived factor-1 (SDF-1) over-expression remodelled the hearts of high risk patients with ischaemic heart failure in the phase II STOP-HF trial.

Many presenters in Clinical Breakthroughs also provided their presentation slides to PACE for you to download.